Sign In
Buy CSLLY
$16.35
-0.280 (-1.68%)
At Close: Jun 03, 2026
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
02:00am, Tuesday, 29'th Apr 2025
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
12:40pm, Monday, 07'th Apr 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
12:40pm, Tuesday, 18'th Mar 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or CSL Limited Sponsored ADR (CSLLY). But which of these two s
BMRN or CSLLY: Which Is the Better Value Stock Right Now?
12:46pm, Friday, 28'th Feb 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks
ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation enab
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
08:30am, Friday, 14'th Feb 2025
- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
08:00am, Friday, 14'th Feb 2025
WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
07:00am, Thursday, 13'th Feb 2025
- ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading t
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 12'th Feb 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks
New Strong Sell Stocks for February 12th
07:26am, Wednesday, 12'th Feb 2025
ARES, CSLLY and CABGY have been added to the Zacks Rank #5 (Strong Sell) List on February 12, 2025.
CSL Limited (CSLLY) Q2 2025 Earnings Call Transcript
08:25am, Tuesday, 11'th Feb 2025
CSL Limited (OTCQX:CSLLY) Q2 2025 Results Earnings Conference Call February 10, 2025 7:00 PM ET Company Participants Chris Cooper - Vice President and Head of Investor Relations Paul McKenzie - Chief
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
01:04pm, Friday, 07'th Feb 2025
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene de
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal level
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
10:38am, Friday, 13'th Dec 2024
If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
12:41pm, Thursday, 21'st Nov 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with t
